NUCRYST Pharmaceuticals to Release Second Quarter 2008 Financial Results on Tuesday, August 12, 2008

    WAKEFIELD, MA, Aug. 5 /CNW/ - NUCRYST Pharmaceuticals Corp. (NASDAQ:  
NCST; TSX: NCS), a developer and manufacturer of medical products that fight
infection and inflammation, announced plans to release its financial results
for the second quarter 2008 on Tuesday, August 12, 2008.
    The company will host a conference call at 9:00 AM ET on Wednesday,
August 13, 2008 to discuss the financial results for the quarter.

    Conference call details:

    Date:        Wednesday, August 13, 2008
    Time:        9:00 AM ET
    Dial-in:     877-419-6593 (U.S.)
                 719-325-4916 (International)
    Web cast: (Investor Relations section)

    An audio replay of the call will be available for seven days:
    Access:      888-203-1112 (U.S.)
                 719-457-0820 (International)
                 Replay Passcode: 9742016

    In addition to the standard disclosure over wire services, a news release
and financial statements will be posted on the NUCRYST website.

    About NUCRYST Pharmaceuticals

    NUCRYST Pharmaceuticals (NASDAQ:   NCST; TSX: NCS) develops, manufactures
and commercializes medical products that fight infection and inflammation
using SILCRYST(TM), its patented atomically disordered nanocrystalline silver
technology. NUCRYST licensed world-wide rights for SILCRYST(TM) wound care
coating products to Smith & Nephew plc, which markets these products in over
30 countries under their Acticoat(TM) trademark. NUCRYST is also developing
pharmaceutical products to address medical conditions that are characterized
by pain, infection and inflammation. The Company has developed its proprietary
nanocrystalline silver in a powder form, referred to as NPI 32101 for use in
medical devices and as an active pharmaceutical ingredient.

    Acticoat(TM) is a trademark of Smith & Nephew plc
    SILCRYST(TM) is a trademark of NUCRYST Pharmaceuticals Corp.

    %SEDAR: 00023031E

For further information:

For further information: David B. Holtz, Vice President and Chief
Financial Officer, NUCRYST Pharmaceuticals, (781) 224-1444,;
Gregory W. Gin, Lazar Partners, (212) 867-1762

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890